Dyadic International, Inc. Appoints Patrick Lucy to its Board of Directors
January 11, 2021 at 08:39 am EST
Share
Dyadic International, Inc. announced on January 11, 2021, that Patrick Lucy has been appointed to its Board of Directors, effective January 8, 2021. Mr. Lucy will serve as a member of the Board's Science and Technology Committee, effective immediately. As a non-employee Director of the Company, Mr. Lucy will receive annual cash compensation of $60,000 and a new director grant of 35,000 options to purchase the Company’s shares. He will also receive annual option grants consistent with the Company’s director compensation program.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
